



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 265/30, A61K 31/535		A1	(11) International Publication Number: WO 92/18489
			(43) International Publication Date: 29 October 1992 (29.10.92)
<p>(21) International Application Number: PCT/GB92/00733</p> <p>(22) International Filing Date: 22 April 1992 (22.04.92)</p> <p>(30) Priority data: 9108629.8 23 April 1991 (23.04.91) GB</p> <p>(71) Applicant (<i>for all designated States except US</i>): THE WELL-COME FOUNDATION LIMITED [GB/GB]; Unicorn House, 160 Euston Road, London NW1 2BP (GB).</p> <p>(72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): MEHTA, Nariman, Bomanshaw [US/US]; 26644 Evert Street, Leesburg, FL 34748-8009 (US). BOSWELL, Grady, Evan [US/US]; 1235 Selwyn Lane, Cary, NC 27511 (US). KELLEY, James, Leroy [US/US]; 10928 Raven Rock Drive, Raleigh, NC 27614 (US).</p>		<p>(74) Agent: STOTT, Michael, John; The Wellcome Foundation Limited, Langley Court, Beckenham, Kent BR3 3BS (GB).</p> <p>(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), HU, IT (European patent), JP, LU (European patent), MC (European patent), NL (European patent), SE (European patent), US.</p> <p>Published <i>With international search report.</i></p>	
(54) Title: ARYLMORPHOLINE, PREPARATION AND USE			
<div style="text-align: center;"> <p style="text-align: right;">(I)</p> </div>			
(57) Abstract			
<p>Novel morpholines of formula (I) and their salts, wherein R and R¹ are each either hydrogen or fluorine and R² is hydrogen or methyl. The compounds have a variety of uses in human medicine, in particular in the treatment of mental disorders such as depression.</p>			

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	RU	Russian Federation
CG	Congo	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR	Republic of Korea	SE	Sweden
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
DE	Germany	MC	Monaco	TG	Togo
DK	Denmark			US	United States of America

ARYLMORPHOLINE, PREPARATION AND USE

The present invention relates to novel morpholines useful in medicine, to processes for preparing them, to pharmaceutical formulations containing them and their preparation, to the use of the compounds in medicine and to novel chemical intermediates therefor and the preparation thereof.

It has been found that novel morpholine compounds represented by formula (I)



wherein R and R¹ are each either hydrogen or fluorine and R² is hydrogen or methyl, and salts thereof, have antidepressant activity as demonstrated by widely accepted techniques used in the art of pharmacology for determining antidepressant activity, for example, the tetrabenazine-induced sedation test in rodents. Advantageously these compounds do not produce any significant degree of locomotor stimulation and are essentially free of proconvulsant activity in the therapeutic dose range.

Structural formula (I) should be understood to extend to and embrace all geometric and optical isomers.

Preferred compounds within formula (I) are:


(+ -)-(2R*, 3R*, 5S*)-2-(3-fluorophenyl)-3,5-dimethylmorpholine
(2S, 3S, 5R)-2-(3,4-difluorophenyl)-3,5-dimethylmorpholine
(+ -)-(2R*, 3R*, 5S*)-2-(3-fluorophenyl)-3,4,5-trimethylmorpholine
(+ -)-(2R*, 3R*, 5S*)-2-(4-fluorophenyl)-3,5-dimethylmorpholine
(2R, 3R, 5S)-2-(4-fluorophenyl)-3,5-dimethylmorpholine
(+ -)-(2R*, 3R*, 5S*)-2-(2,3-difluorophenyl)-3,5-dimethylmorpholine
(2S, 3S, 5R)-2-(3-fluorophenyl)-3,4,5-trimethylmorpholine
(+ -)-(2R*, 3R*, 5S*)-2-(4-fluorophenyl)-3,4,5-trimethylmorpholine and
(2S, 3S, 5R)-2-(4-fluorophenyl)-3,5-dimethylmorpholine
and salts thereof, in particular pharmaceutically acceptable salts, the first
two of which (together with their salts) being particularly preferred.

The compounds of formula (I) and their salts may be synthesized by the methods known in the art for the preparation of compounds of analogous structure and in this regard reference is made, by way of illustration only, to the following standard texts:

- i) "Protective Groups in Organic Chemistry" ed. J.F.W. McOmie, Plenum Press (1973), ISBN 0-306-30717-0;
- ii) "Compendium of Organic Synthetic Methods" ed. I.T. Harrison and S. Harrison, Wiley-Interscience, Vol. I (1971) ISBN 0-471-35550-X, Vol. II (1974) ISBN 0-471-35551-8 and Vol. III (ed. L.S. Hegedus and L. Wade) (1977) ISBN 0-471-36752-4; and


- iii) Rodd's "Chemistry of Carbon Compounds" second edition, Elsevier Publishing Company.

Thus the compounds of formula (I) can be prepared by cyclization of the corresponding compound of formula (II) wherein R, R¹ and R² are as defined for formula (I) by treatment with a dehydrating agent such as sulfuric acid in a solvent such as dichloromethane at 0°C or by reaction with p-toluenesulfonic acid as a melt at 110-160°C.





The compounds of formula (I) wherein R² is methyl may also be prepared by methylation of the corresponding compound of formula (I) wherein R² is hydrogen using for example aqueous formaldehyde and formic acid at 50-100°C; methyl iodide in acetonitrile at 50-100°C; formylation followed by reduction; and reaction with diazomethane in the presence of a Lewis acid such as borontrifluoride etherate.

Compounds of formula (II) can be prepared by selective reduction of the corresponding morpholinol of formula (III) wherein R, R¹ and R² are as defined for formula (I) using a mild reducing agent such as sodium borohydride in 95% ethanol or diborane in tetrahydrofuran, or any other appropriate reducing agent.



The morpholinols of formula (III) can be made by reacting a compound (IV) having the appropriate chirality with a compound of formula (V) wherein R, R¹ and R² are as defined for formula (I) and L is a leaving atom or group such as halo (for example, bromo, chloro or iodo) in a suitable solvent such as acetonitrile, ethanol, methanol or dichloromethane in the presence of a base, for example, 2,6-lutidine. The reaction may conveniently be performed at a temperature in the range of 20° to 40°C.



It will be appreciated that use in this manner of a racemic compound (IV), i.e. a dl-2-amino-1-propanol, affords the (+-)-(2R*, 3R*, 5S*) racemate of formula (III) while an R-2-amino-1-propanol selectively provides the (2S, 3S, 5R) compound and an S-2-amino-1-propanol selectively provides the (2R, 3R, 5S) compound.

It will further be understood that a (+-)-(2R*, 3R*, 5S*) racemate of formula (III) will ultimately provide, in the manner above described, the (+-)-(2R*, 3R*, 5S*) racemate of formula (I), whilst the (2S, 3S, 5R) and (2R, 3R, 5S) compounds (III) will likewise afford the (2S, 3S, 5R) and (2R, 3R, 5S) compounds (I) respectively.

The (2S, 3S, 5R) compounds and (2R, 3R, 5S) compounds of formulae (I) and (III) can also be selectively obtained by resolution of the appropriate (+-)-(2R*, 3R*, 5S*) racemate. This may be accomplished in a conventional manner, by forming the diastereomeric salts of the latter with an optically active acid, for example (+)- or (-)-tartaric acid or (+)- or (-)-dibenzoyl-L- or D-tartaric acid monohydrate, in an appropriate solvent, for example aqueous ethanol, followed by recrystallization of the appropriate diastereomeric salt and isolation of the morpholine/morpholinol free base.

The compounds of formula (I) and their pharmaceutically acceptable salts may be used in the treatment of depression in human beings, identified as being depressed, the treatment comprising the administration of an antidepressant effective, non-toxic amount (dose), preferably in a unit dosage form, of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

Depression states in the treatment of which the said compounds and salts are particularly useful are those classified as affective disorders in the Diagnostic and Statistical Manual of

Mental Disorders, Third Edition - Revised, American Psychiatric Association, Washington, D.C. (1987) (DSM-III-R), including the mood disorders (DSM-III-R, 296.2X to 296.6X), other specific affective disorders (301.13 and 300.40) and bipolar and depressive disorders not otherwise specified (296.70 and 311.00).

Other uses in human therapy for these compounds and salts include the treatment of the following conditions, the classifications (where indicated) being those adopted in DSM-III-R:

- anxiety disorders, including phobic neuroses (300.00, 300.21, 300.22, 300.23 and 300.29), anxiety neuroses (300.01, 300.02 and 300.30) and post-traumatic stress disorder (309.89)
- attention deficit disorders (314.00 and 314.01)
- eating disorders, including anorexia nervosa (307.10) and bulimia (307.51)
- personality disorders, including borderline personality disorder (301.83)
- sexual dysfunctions, including hypoactive sexual desire disorder (302.71), female sexual arousal disorder or male erectile disorder (302.72), inhibited female orgasm (302.73), inhibited male orgasm (302.74), premature ejaculation (302.75), dyspareunia (302.76), vaginismus (306.51) and sexual dysfunction not otherwise specified (302.70)

- headaches, including migraine, muscle contraction and mixed (i.e. combination of migraine and muscle contraction) headaches
- narcolepsy-cataplexy syndrome, a condition characterized by excessive sleepiness (narcolepsy) often taking the form of sleep attacks, episodes of a seemingly irresistible need to sleep usually lasting for about fifteen minutes or less, together with brief (often lasting less than a minute) periods of loss of muscle tone (cataplexy) occurring in association with the expression of emotion.

The compounds and salts may further be used in human medicine:

- to alleviate symptoms of withdrawal consequent upon the cessation of illicit drug abuse
- to potentiate the analgesia induced by morphine or a like opiate analgesic, for example in the care and treatment of terminally-ill cancer patients
- to prevent functional impairment and drowsiness following administration of a drowsiness-inducing benzodiazepine tranquilizer; suitable indications for concomitant administration of a said compound or salt and such a benzodiazepine include a) treatment of mixed anxiety and depression in situations where functional impairment or drowsiness is undesirable, and b) treatment of anxiety in situations where functional impairment or drowsiness is undesirable

- to prevent memory loss following administration of a benzodiazepine tranquilizer
- to restore mental functioning acutely impaired consequent upon ethanol ingestion
- to suppress prolactin release or secretion, for example in the suppression of lactation postpartum or in the treatment of galactorrhoea, hyperprolactinaemia, amenorrhoea resulting from hyperprolactinaemia and prolactin-sensitive mammary cancer
- to treat memory loss and other memory deficits associated with benign senility.

For each of the foregoing indications, the preferred dosage for parenteral (including subcutaneous, intramuscular and intravenous) administration of a compound of formula (I) or salt thereof (estimated as the base) is in the range 0.05 mg/kg to 10 mg/kg of body weight per day. The most preferred dosage is in the range of 0.25 mg/kg to 5 mg/kg of body weight per day.

For the oral, rectal, topical(including buccal and sublingual) or transdermal mode of administration, the preferred dosage of a compound of formula (I) or salt thereof (estimated as the base) is in the range 0.25 mg/kg to 20 mg/kg of body weight per day while the most preferred dosage is in the range of 0.5 mg/kg to 10 mg/kg of body weight per day.

As will be understood, the precise dosage will depend upon a number of clinical factors, for example, the age of the recipient and the condition in question and its severity.

The preferred unit dosage of a compound of formula (I) or salt thereof (estimated as the base) for oral, rectal or topical (including buccal and sublingual) administration is in the range 2.5 mg to 200 mg with the more preferred unit dosage being in the range 5 mg to 150 mg and the most preferred unit dosage being in the range 10 mg to 100 mg. For parenteral (including subcutaneous, intramuscular and intravenous) administration, the preferred unit dosage is in the range 1 mg to 125 mg with the more preferred unit dosage being in the range 2.5 mg to 100 mg and the most preferred unit dosage being in the range 5 mg to 50 mg.

All the above doses are expressed in terms of the weight of the base but a compound of formula (I) is preferably administered in the form of a pharmaceutically acceptable salt thereof.

A compound of formula (I) or salt thereof is preferably administered four times daily although this may vary according to the patient being treated, and at the physician's discretion.

While it is possible for the active compound, i.e., compound of formula (I) or pharmaceutically acceptable salt thereof, to be administered alone as the raw chemical, it is preferable to present it as a pharmaceutical formulation comprising a compound of formula (I) (or a pharmaceutically acceptable salt thereof) together with an acceptable carrier therefor.

The carrier should be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

Conveniently the active compound comprises from 5 to 95% by weight of the formulation.

The formulations include those suitable for oral, rectal, topical (including buccal and sublingual), parenteral (including subcutaneous, intramuscular and intravenous) or transdermal administration.

The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active compound into association with a carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier or a finely divided solid carrier or both and then, if necessary, shaping the product.

Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets or lozenges, each containing a predetermined amount of the active compound; as a powder or granules including microencapsulated or time-release forms; or as a suspension or solution in an aqueous liquid or non-aqueous liquid such as a syrup, an elixir, an emulsion or a draught.

A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine, the active compound being in a free-flowing form such as a powder or granules

optionally mixed with a binder, disintegrant, lubricant, inert diluent, surface active agent or dispersing agent. Molded tablets comprising a mixture of the powdered active compound with any suitable carrier may be made by molding in a suitable machine.

Formulations suitable for rectal administration may be presented as a suppository with a conventional carrier such as cocoa butter, hydrogenated fats or hydrogenated fatty carboxylic acids.

Formulations suitable for topical administration in the mouth, for example buccally or sublingually, include lozenges comprising the active compound in a flavored basis such as sucrose and acacia or tragacanth, and pastilles comprising the active compound in a basis such as gelatin and glycerin or sucrose and acacia.

Formulations suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the active compound which is preferably isotonic with the blood of the intended recipient. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampules and vials, and may be stored in a freeze-dried state requiring only the addition of the sterile liquid carrier, for example water, just prior to use. As an alternative possibility, the active compound may be presented in the form of liposomes.

Formulations suitable for transdermal administration may be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Such patches suitably contain the active compound 1) in an optionally buffered, aqueous solution, 2) dissolved and/or dispersed in an adhesive or 3) dispersed in a polymer, a suitable concentration of the active compound being in the

range of about 1% to 35%, preferably about 3% to 15% (w/w). As one particular possibility, the active compound may be delivered from the patch by electrotransport or iontophoresis as generally described in Pharmaceutical Research, 3(6), 318 (1986).

In addition to the aforementioned ingredients, the formulations of this invention may further include one or more accessory ingredient(s) selected as appropriate from diluents, buffers, flavoring agents, binders, disintegrants, surface active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.

When used in medicine, the salts of a compound of formula (I) should be pharmaceutically acceptable, but pharmaceutically unacceptable salts may conveniently be used to prepare the corresponding free base or pharmaceutically acceptable salts thereof and are included within the scope of this invention.

Such pharmaceutically acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, salicylic, *p*-toluenesulfonic, tartaric, citric, methanesulfonic, maleic, formic, malonic, succinic, isethionic, lactobionic, naphthalene-2-sulfonic, sulfamic, ethanesulfonic and benzenesulfonic.

Published patent specification US-A-4 803 200 discloses a large class of dialkanolamines, thiol analogues and 1,4-oxazine condensation derivatives thereof, embracing the morpholine compounds of formula (I) herein, and teaches their use in combatting viral infections in animals, especially mammals such as cattle, sheep, goats, horses, buffalo, deer and the like, particularly those viral infections associated with shipping fever.

The said US-A specification further states that certain of the subject compounds were prepared and reported to be antitumour agents in the following disclosures:

R.E. Lutz and R.S. Murphey in J. Am. Chem. Soc. 71, 478 (1949),

R.E. Lutz and J.W. Baker in J. Org. Chem. 21, 49 (1956), and

R.E. Lutz, J.A. Freek and R.S. Murphey in J. Am. Chem. Soc. 70, 2015 (1948).

None of the compounds specifically identified in either the US-A specification itself or the said disclosures falls within formula (I) herein.

It will be appreciated from the foregoing that in various aspects the present invention provides the following, inter alia:

- a) compounds of formula (I) as hereinbefore defined and salts thereof together with methods for their preparation as hereinbefore described
- b) pharmaceutical formulations as hereinbefore defined together with methods for their preparation as hereinbefore described
- c) compounds of formula (I) and pharmaceutically acceptable salts thereof for use in human or veterinary medicine, in particular in the treatment of depression in human beings
- d) use of compounds of formula (I) and pharmaceutically acceptable salts thereof for the manufacture of medicaments for the treatment of depression in human beings.

- e) a method for the treatment of depression in human beings comprising administration of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
- f) novel chemical intermediates together with methods for their preparation as hereinbefore described.

The following Examples are provided by way of illustration of the present invention and should in no way be construed as a limitation thereof.

Example 1: (+-)-(2R*, 3R*, 5S*)-2-(3-fluorophenyl)-3,5-dimethylmorpholine hydrochloride

To a solution of 3'-fluoropropiophenone (Aldrich Chemical Co., Milwaukee, WI 53233) (61 g, 0.4 mole) in dioxane (300 ml) was added a solution of dioxane dibromide (99 g, 0.4 mole) in dioxane (200 ml). [The dioxane dibromide solution was prepared by the addition of bromine (64 g, 0.4 mole) to dioxane (200 ml)]. The reaction mixture was stirred for one hour at room temperature, diluted with water and extracted with dichloromethane. The organic layers were combined, washed with brine, dried (potassium carbonate), and concentrated under reduced pressure to yield crude 2-bromo-3'-fluoropropiophenone (103 g).

To a solution of 2-bromo-3'-fluoropropiophenone (46.2 g, 0.2 mole) in acetonitrile (150 ml) was added a solution of dl-2-amino-1-propanol (Aldrich Chemical Co., Milwaukee, WI 53233) (16.5 g, 0.22 mole) and 2,6-lutidine (23.6 g, 0.22 mole) in acetonitrile (100 ml). The resulting mixture was stirred for 72 hours at room temperature.

The reaction was filtered, the solid was washed with a small amount of acetonitrile followed by dry diethyl ether and dried to give 29.6 g of (+-)-(2R*, 3R*, 5S*)-3,5-dimethyl-2-(3-fluorophenyl)-2-morpholinol hydrobromide.

To a solution of (+-)-(2R*, 3R*, 5S*)-3,5-dimethyl-2-(3-fluorophenyl)-2-morpholinol hydrobromide (29.6 g, 0.097 mole) in 50-50 ethanol-water (200 ml) was added a solution of sodium borohydride (14.6 g, 0.387 mole) in water (200 ml) at 0°C. The resulting mixture was stirred for 16 hours at room temperature, treated with concentrated hydrochloric acid and concentrated under reduced pressure. The residue was dissolved in water, basified (50% aqueous sodium hydroxide), and extracted with dichloromethane. The organic layers were combined, washed with brine, dried (potassium carbonate), and concentrated under reduced pressure to give 23.6 g of (1R*, 2S*)-2-[[[(1R_S)-2-hydroxy-1-methylethyl]amino]-1-(3-fluorophenyl)propanol as a white solid.

To concentrated H₂SO₄ (75 ml) was added a solution of (1R*, 2S*)-2-[[[(1R_S)-2-hydroxy-1-methylethyl]amino]-1-(3-fluorophenyl)propanol (21.6 g, 0.095 mole) in dichloromethane (100 ml) at 0°C. The resulting mixture was stirred for 16 hours at room temperature and diluted with ice water. The aqueous phase was basified with 40% aqueous sodium hydroxide and extracted with diethyl ether. The diethyl ether layers were combined, washed with brine, dried (sodium sulfate), and concentrated under reduced pressure to yield the crude reaction product as the free base. The crude product was dissolved in diethyl ether and treated with ethereal hydrogen chloride. Recrystallization from ethanol-diethyl ether mixtures gave 17.7 g of (+-)-(2R*, 3R*, 5S*)-2-(3-fluorophenyl)-3,5-dimethylmorpholine hydrochloride as a white solid, m.p. 268-269°C.

NMR-¹H: (DMSO-d₆) δ 0.98 (d, 3H, CH₃), 1.22 (d, 3H, CH₃), 3.42 (broad multiplet, 2H, CH), 3.62 (dd, 1H, CH₂, J = 11.09, 11.61), 4.02 (dd, 1H, CH₂, J = 3.12, 11.91), 4.44 (d, 1H, CH, J = 9.92), 7.15-7.49 (aromatic H's), 9.46 and 10.00 (broad, 2H, HCl and NH).

Elemental Analysis: Calcd. for C₁₂H₁₇ClFNO (m.w. 245.724): C, 58.65%; H, 6.97%; N, 5.70%. Found: C, 58.72%; H, 7.01%; N, 5.68%.

Example 2: (2S, 3S, 5R)-2-(3,4-difluorophenyl)-3,5-dimethylmorpholine hydrochloride.

To 3',4'-difluoropropiophenone (Alfa Products, Danvers, MA 01923) (90.5 g, 0.53 mole) was added a solution of dioxane dibromide (131.4 g, 0.53 mole) in dioxane (500 ml). The reaction was worked up as in Example 1 to yield crude 2-bromo-3',4'-difluoropropiophenone (130.5 g).

To a solution of 2-bromo-3',4'-difluoropropiophenone (47.3 g, 0.19 mole) in acetonitrile (100 ml) was added a solution of R-2-amino-1-propanol (Aldrich Chemical Co., Milwaukee, WI 53233) (15 g, 0.20 mole) and 2,6-lutidine (23.6 g, 0.22 mole) in acetonitrile (50 ml). The reaction was worked up as in Example 1 to give 26.9 g of (2S, 3S, 5R)-2-(3,4-difluorophenyl)-3,5-dimethyl-2-morpholinol hydrobromide.

A solution of (2S, 3S, 5R)-2-(3,4-difluorophenyl)-3,5-dimethyl-2-morpholinol hydrobromide (4.85 g, 0.015 mole) in water was basified with 40% aqueous sodium hydroxide and extracted with diethyl ether. The diethyl ether layers were combined, washed with brine, dried (potassium carbonate) and concentrated under reduced pressure to yield the free base. The free base was dissolved in ether and treated with ethereal hydrogen chloride. The hydrochloride salt was recrystallized from ethanol-

diethyl ether mixtures to give 3.26 g of (2S, 3S, 5R)-2-(3,4-difluorophenyl)-3,5-dimethyl-2-morpholinol hydrochloride as a white solid. m.p. 223-225°C dec.

Elemental Analysis: Calcd. for $C_{12}H_{16}ClF_2NO_2$ (m.w. 279.71): C, 51.52%; H, 5.77%; N, 5.01%. Found: C, 51.54%; H, 5.80%; N, 4.98%. $[\alpha]_D^{20} = +42.16^\circ$ (c = 0.676, abs. ethanol).

To a solution of (2S, 3S, 5R)-2-(3,4-difluorophenyl)-3,5-dimethyl-2-morpholinol hydrobromide (25.4 g, 0.078 mole) in 50-50 ethanol-water (300 ml) was added a solution of sodium borohydride (11.9 g, 0.31 mole) in water (120 ml) at 0°C. The resulting mixture was stirred for 16 hours at room temperature. The reaction mixture was treated with concentrated hydrochloric acid and concentrated under reduced pressure. The residue was dissolved in water, basified (40% aqueous sodium hydroxide), and extracted with dichloromethane. The organic layers were combined, washed with brine and dried (potassium carbonate) to give a solution of (1R, 2S)-1-(3,4-difluorophenyl)-2-(((1R)-2-hydroxy-1-methylethyl)amino)propanol in dichloromethane (500 ml). 50 ml of the solution was concentrated under reduced pressure to yield 1.9 g of the free base as a white solid. The free base was dissolved in diethyl ether and treated with ethereal hydrogen chloride. The hydrochloride salt was recrystallized from ethanol-diethyl ether mixtures to give 1.1 g of (1R, 2S)-1-(3,4-difluorophenyl)-2-(((1R)-2-hydroxy-1-methylethyl)amino)propanol hydrochloride as a white solid. m.p. 116-117°C.

Elemental Analysis: Calcd. for $C_{12}H_{18}ClF_2NO_2$ (m.w. 281.73): C, 51.16%; H, 6.44%; N, 4.97%. Found: C, 51.06%; H, 6.48%; N, 4.95%. $[\alpha]_D^{20} = -29.0^\circ$ (95% ethanol).

To concentrated H_2SO_4 (100 ml) was added a solution of (1R, 2S)-1-(3,4-difluorophenyl)-2-[[[(1R)-2-hydroxy-1-methylethyl]amino]propanol (17.1 g, 0.07 mole) in dichloromethane (100 ml). The reaction was worked up as in Example 1 to yield the crude reaction product as the free base. The crude product was dissolved in diethyl ether and treated with ethereal hydrogen chloride. The hydrochloride salt was recrystallized from ethanol-diethyl ether mixtures to give 9.2 g (49.8% of theory) of (2S, 3S, 5R)-2-(3,4-difluorophenyl)-3,5-dimethylmorpholine hydrochloride as a white solid. m.p. 318°C . $[\alpha]_D^{20} = +24.6^\circ$ (c = 0.710, 95% ethanol).

NMR-1H: (DMSO- d_6) δ 0.96 (d, 3H, CH_3), 1.20 (d, 3H, CH_3), 3.42 (broad multiplet, 2H, CH), 3.59 (dd, 1H, CH_2 , J = 10.94, 11.67), 4.01 (dd, 1H, CH_2 , J = 2.97, 11.72), 4.40 (d, CH, J = 9.81), 7.21-7.58 (aromatic H's), 9.36 and 9.95 (broad, 2H, HCl and NH).

Elemental Analysis: Calcd. for $\text{C}_{12}\text{H}_{16}\text{ClF}_2\text{NO}$ (m.w. 263.71): C, 54.65%; H, 6.12%; N, 5.31%. Found: C, 54.74%; H, 6.15%; N, 5.30%.

The following compounds of Examples 3-13 were synthesized from the appropriate starting materials using procedures analogous to those described in Example 1 and Example 2 above. In the case of the (2R, 3R, 5S) compounds, S-2-amino-1-propanol (Aldrich Chemical Co., Milwaukee, WI 53233) was employed.

Example 3: (2S, 3S, 5R)-2-(3-fluorophenyl)-3,5-dimethylmorpholine hydrochloride. m.p. $324-325^\circ\text{C}$. $[\alpha]_D^{20} = +20.9^\circ$ (c = 0.721, 95% ethanol).

NMR-¹H: (DMSO-d₆) δ 0.97 (d, 3H, CH₃), 1.21 (d, 3H, CH₃), 3.41 (broad multiplet, 2H, CH), 3.58 (dd, 1H, CH₂, J = 10.94, 11.72), 4.01 (dd, 1H, CH₂, J = 2.97, 11.87), 4.42 (d, 1H, CH, J = 9.96), 7.15-7.48 (aromatic H's), 9.42 and 9.98 (broad, 2H, HCl and NH).

Elemental Analysis: Calcd. for C₁₂H₁₇ClFNO (m.w. 245.72): C, 58.66%; H, 6.97%; N, 5.70%. Found: C, 58.72%; H, 7.00%; N, 5.66%.

Example 4: (2R,3R,5S)-2-(3-fluorophenyl)-3,5-dimethylmorpholine hydrochloride.
m.p. 323-325°C. [α]_D²⁰ = -23.1° (c = 0.671, 95% ethanol).

NMR-¹H: (DMSO-d₆) δ 0.98 (d, 3H, CH₃), 1.22 (d, 3H, CH₃), 3.43 (broad multiplet, 2H, CH), 3.63 (dd, 1H, CH₂, J = 10.98, 11.72), 4.02 (dd, 1H, CH₂, J = 3.08, 11.71), 4.44 (d, 1H, CH, J = 9.81), 7.17-7.49 (aromatic H's), 9.46 and 10.01 (broad, 2H, HCl and NH).

Elemental Analysis: Calcd. for C₁₂H₁₇ClFNO (m.w. 245.72): C, 58.66%; H, 6.97%; N, 5.70%. Found: C, 58.74%; H, 7.01%; N, 5.71%.

Example 5: (+-)-(2R*, 3R*, 5S*)-2-(2-fluorophenyl)-3,5-dimethylmorpholine hydrochloride.
m.p. 228-230°C.

NMR-¹H: (DMSO-d₆) δ 1.01 (d, 3H, CH₃), 1.22 (d, 3H, CH₃), 3.46 (broad multiplet, 2H, CH), 3.66 (dd, 1H, CH₂, J = 10.94, 12.15), 4.04 (dd, 1H, CH₂, J = 3.04, 11.65), 4.78 (d, 1H, CH, J = 9.96), 7.20-7.55 (aromatic H's), 9.45 and 9.95 (broad, 2H, HCl and NH).

Elemental Analysis: Calcd. for $C_{12}H_{17}ClFNO$ (m.w. 245.72): C, 58.66%; H, 6.97%; N, 5.70%. Found: C, 58.78%; H, 7.02%; N, 5.66%.

Example 6: (2R, 3R, 5S)-2-(4-fluorophenyl)-3,5-dimethylmorpholine hydrochloride.
m.p. 299-300°C. $[\alpha]_D^{20.5} = -24.9^\circ$ (c = 0.708, 95% ethanol).

NMR- 1H : (DMSO- d_6) δ 0.96 (d, 3H, CH_3), 1.22 (d, 3H, CH_3), 3.42 (broad multiplet, 2H, CH), 3.62 (dd, 1H, CH_2 , J = 10.94, 11.72), 4.01 (dd, 1H, CH_2 , J = 3.08, 11.72), 4.41 (d, 1H, CH, J = 9.96), 7.17-7.47 (aromatic H's), 9.42 and 9.96 (broad, 2H, HCl and NH).

Elemental Analysis: Calcd. for $C_{12}H_{17}ClFNO$ (m.w. 245.72): C, 58.66%; H, 6.97%; N, 5.70%. Found: C, 58.73%; H, 7.00%; N, 5.66%.

Example 7: (+-)-(2R*, 3R*, 5S*)-2-(2,3-difluorophenyl)-3,5-dimethylmorpholine hydrochloride.
m.p. 285-286°C.

NMR- 1H : (DMSO- d_6) δ 1.04 (d, 3H, CH_3), 1.23 (d, 3H, CH_3), 3.41 (broad multiplet, 2H, CH), 3.69 (dd, 1H, CH_2 , J = 11.17, 11.92), 4.04 (dd, 1H, CH_2 , J = 3.32, 11.93), 4.84 (d, 1H, CH, J = 9.96), 7.21-7.53 (aromatic H's), 9.58 and 10.05 (broad, 2H, HCl and NH).

Elemental Analysis: Calcd. for $C_{12}H_{16}ClF_2NO$ (m.w. 263.71): C, 54.65%; H, 6.12%; N, 5.31%. Found: C, 54.57%; H, 6.14%; N, 5.27%.

Example 8: (+-)-(2R*, 3R*, 5S*)-2-(3,4-difluorophenyl)-3,5-dimethylmorpholine hydrochloride.

m.p. 256-257°C.

NMR-¹H: (DMSO-d₆) δ 0.98 (d, 3H, CH₃), 1.21 (d, 3H, CH₃), 3.46 (broad multiplet, 2H, CH), 3.61 (dd, 1H, CH₂, J = 10.94, 11.72), 4.01 (dd, 1H, CH₂, J = 3.09, 11.72), 4.42 (d, 1H, CH, J = 9.97), 7.22-7.59 (aromatic H's), 9.42 and 10.02 (broad, 2H, HCl and NH).

Elemental Analysis: Calcd. for C₁₂H₁₆ClF₂NO (m.w. 263.71): C, 54.65%; H, 6.12%; N, 5.31%. **Found:** C, 54.73%; H, 6.15%; N, 5.25%.

Example 9: (+-)-(2R*, 3R*, 5S*)-2-(3,5-difluorophenyl)-3,5-dimethylmorpholine hydrochloride.

m.p. 331-334°C (sublimed).

NMR-¹H: (DMSO-d₆) δ 1.00 (d, 3H, CH₃), 1.22 (d, 3H, CH₃), 3.39 (broad multiplet, 2H, CH), 3.63 (dd, 1H, CH₂, J = 10.94, 11.87), 4.01 (dd, 1H, CH₂, J = 3.12, 11.76), 4.46 (d, 1H, CH, J = 9.92), 7.11-7.31 (aromatic H's), 9.52 and 10.16 (broad, 2H, HCl and NH).

Elemental Analysis: Calcd. for C₁₂H₁₆ClF₂NO (m.w. 263.71): C, 54.65%; H, 6.12%; N, 5.31%. **Found:** C, 54.57%; H, 6.12%; N, 5.28%.

Example 10: (+-)-(2R*, 3R*, 5S*)-3,5-dimethyl-2-(2,4,5-trifluorophenyl)morpholine hydrochloride.

m.p. 260-263°C.

NMR-¹H: (DMSO-d₆) δ 1.02 (d, 3H, CH₃), 1.21 (d, 3H, CH₃), 3.47 (broad multiplet, 2H, CH), 3.65 (dd, 1H, CH₂, J = 11.09, 11.91), 4.03 (dd, 1H, CH₂, J = 3.32, 12.11), 4.75 (d, 1H, CH, J = 9.92), 7.56 - 7.73 (aromatic H's), 9.45 and 10.01 (broad, 2H, HCl and NH).

Elemental Analysis: Calcd. for C₁₂H₁₅ClF₃ NO (m.w. 281.71): C, 51.16%; H, 5.37%; N, 4.97%. Found: C, 51.26%; H, 5.40%; N, 4.98%.

Example 11: (+-)-(2R*, 3R*, 5S*)-2-(2,4-difluorophenyl)-3,5-dimethylmorpholine hydrochloride.
m.p. 254-256°C.

NMR-¹H: (DMSO-d₆) δ 1.01 (d, 3H, CH₃), 1.22 (d, 3H, CH₃), 3.42 (broad multiplet, 2H, CH), 3.66 (dd, 1H, CH₂, J = 11.09, 11.91), 4.02 (dd, 1H, CH₂, J = 3.32, 11.96), 4.76 (d, 1H, CH, J = 9.96), 7.12-7.63 (aromatic H's), 9.54 and 10.05 (HCl and NH).

Elemental Analysis: Calcd. for C₁₂H₁₆ClF₂ NO (m.w. 263.71): C, 54.65%; H, 6.12%; N, 5.31%. Found: C, 54.60%; H, 6.15%; N, 5.32%.

Example 12: (2S, 3S, 5R)-2-(4-fluorophenyl)-3,5-dimethylmorpholine hydrochloride.
m.p. 298-299°C [α]_D^{20.5} = +25.0° (c = 0.814, 95% ethanol).

NMR-¹H: (DMSO-d₆) δ 0.95 (d, 3H, CH₃), 1.21 (d, 3H, CH₃), 3.42 (broad multiplet, 2H, CH), 3.61 (dd, 1H, CH₂, J = 10.99, 11.67), 4.01 (dd, 1H, CH₂, J = 2.93, 11.67), 4.40 (d, 1H, CH, J = 9.97), 7.17-7.47 (aromatic H's), 9.40 and 9.92 (broad, 2H, HCl and NH).

Elemental Analysis: Calcd. for $C_{12}H_{17}ClFNO$ (m.w. 245.72): C, 58.66%; H, 6.97%; N, 5.70%. Found: C, 58.72%; H, 7.01%; N, 5.67%.

Example 13: (+-)-(2R*, 3R*, 5S*)-2-(4-fluorophenyl)-3,5-dimethylmorpholine hydrochloride.

m.p. 238-240°C.

NMR-1H: (DMSO- d_6) δ 0.98 (d, 3H, CH_3), 1.24 (d, 3H, CH_3), 3.41 (broad multiplet, 2H, CH), 3.68 (dd, 1H, CH_2 , $J = 11.13, 11.87$), 3.99 (dd, 1H, CH_2 , $J = 3.34, 12.06$), 4.48 (d, 1H, CH, $J = 9.78$), 7.16 - 7.46 (aromatic H's), 9.75 (broad, 1H, HCl or NH), other proton not included on spectrum.

Elemental Analysis: Calcd. for $C_{12}H_{17}ClFNO$ (m.w. 245.72): C, 58.66%; H, 6.97%; N, 5.70%. Found: C, 58.75%; H, 6.99%; N, 5.69%.

Example 14: (+-)-(2R*, 3R*, 5S*)-2-(3-fluorophenyl)-3,4,5-trimethylmorpholine hydrochloride.

To 95% formic acid (2.5 ml, 0.069 mole) was added (+-)-(2R*, 3R*, 5S*)-2-(3-fluorophenyl)-3,5-dimethylmorpholine (Example 1) (4.1 g, 0.0196 mole) and 37% aqueous formaldehyde (2.2 ml, 0.076 mole). The mixture was heated on a steam bath for 15 hours, treated with 1 N hydrochloric acid and concentrated under reduced pressure. The residue was taken up in water and washed with diethyl ether, and the ether extract was discarded. The aqueous phase was basified with 40% sodium hydroxide and extracted with diethyl ether. The ether layers were combined, washed with brine, dried (potassium carbonate) and concentrated under reduced pressure to give the free base.

The free base was dissolved in ether and treated with ethereal hydrogen chloride. The hydrochloride salt was recrystallized from ethanol-diethyl ether mixtures to give 3.93 g of (+-)-(2R*, 3R*, 5S*)-2-(3-fluorophenyl)-3,4,5-trimethylmorpholine hydrochloride as a white solid.

m.p. 188-191°C.

NMR-1H: (DMSO-d₆) δ 1.04 (d, 3H, CH₃), 1.30 (d, 3H, CH₃), 2.82 (d, 3H, N-Me), 3.48 (broad multiplet, 2H, CH), 3.78 (dd, 1H, CH₂, J = 11.18, 12.26), 4.01 (dd, 1H, CH₂, J = 3.52, 12.50), 4.56 (d, CH, J = 9.96), 7.33-7.38 (aromatic H's), 11.2 (broad, 1H, HCl).

Elemental Analysis: Calcd. for C₁₃H₉ClFNO (m.w. 259.74): C, 60.11%; H, 7.37%; N, 5.39%. Found: C, 60.21%; H, 7.42%; N, 5.37%.

The following compounds of Examples 15-21 were prepared from the appropriate starting materials, using a procedure analogous to that described in Example 14 above.

Example 15: (+-)-(2R*, 3R*, 5S*)-2-(2-fluorophenyl)-3,4,5-trimethylmorpholine 4-toluenesulfonate.

m.p. 161-163°C.

NMR-1H: (DMSO-d₆) δ 1.05 (d, 3H, CH₃), 1.26 (d, 3H, CH₃), 2.28 (s, 3H, ArMe); 2.92 (s, 3H, N-Me); 3.55 (broad m, 2H, CH); 3.66 (dd, 1H, CH₂, J = 11.13, 12.22), 4.09 (dd, 1H, CH₂, J = 3.02, 12.38), 4.76 (d, 1H, CH, J = 10.12), 7.10 - 7.52 (aromatic H's), 9.55 (broad, s, 1H, SO₃H).

Elemental Analysis: Calcd. for $C_{20}H_{26}FNO_4S$ (m.w. 395.49): C, 60.74%; H, 6.63%; N, 3.54%. Found: C, 60.83%; H, 6.67%; N, 3.54%.

Example 16: (2S, 3S, 5R)-2-(3-fluorophenyl)-3,4,5-trimethylmorpholine hydrochloride.
m.p. 192-194°C. $[\alpha]_D^{20} = +35.4^\circ$ (c = 0.713, 95% ethanol).

NMR-1H: (DMSO- d_6) δ 1.07 (d, 3H, CH₃), 1.31 (d, 3H, CH₃), 2.82 (d, 3H, N-Me); 3.51 (broad m, 2H, CH); 3.79 (dd, 1H, CH₂, J = 10.94, 12.65), 4.02 (dd, 1H, CH₂, J = 3.67, 12.55), 4.61 (d, 1H, CH, J = 9.96), 7.17-7.51 (aromatic H's), 11.23 (broad, S, 1H, HCl).

Elemental Analysis: Calcd. for $C_{13}H_{19}ClFNO$ (m.w. 259.75): C, 60.11%; H, 7.37%; N, 5.39%. Found: C, 60.06%; H, 7.40%; N, 5.37%.

Example 17: (2R, 3R, 5S)-2-(4-fluorophenyl)-3,4,5-trimethylmorpholine hydrochloride.
m.p. 193-194°C. $[\alpha]_D^{20} = -38.9^\circ$ (c = 0.703, 95% ethanol).

NMR-1H: (DMSO- d_6) δ 1.05 (d, 3H, CH₃), 1.30 (d, 3H, CH₃), 2.83 (d, 3H, N-Me); 3.48 (broad m, 2H, CH), 3.78 (dd, 1H, CH₂, J = 10.98, 12.70), 4.02 (dd, 1H, CH₂, J = 3.56, 12.54), 4.58 (d, 1H, CH, J = 9.96), 7.17-7.49 (aromatic H's), 11.09 (broad, S, 1H, HCl).

Elemental Analysis: Calcd. for $C_{13}H_{19}ClFNO$ (m.w. 259.75): C, 60.11%; H, 7.37%; N, 5.39%. Found: C, 59.87%; H, 7.42%; N, 5.35%.

Example 18: (+-)-(2R*, 3R*, 5S*)-2-(4-fluorophenyl)-3,4,5-trimethylmorpholine.
m.p. 72-74°C.

NMR-¹H: (CDCl₃) δ 0.84 (d, 3H, CH₃), 1.05 (d, 3H, CH₃), 2.23 (broad m, 1H, CH); 2.32 (s, 3H, N-Me); 2.44 (broad m, 1H, CH), 3.45 (dd, 1H, CH₂, J = 10.94, 10.98), 3.81 (dd, 1H, CH₂, J = 3.32, 11.33); 4.10 (d, 1H, CH, J = 9.18), 7.35-7.01 (aromatic H's).

Elemental Analysis: Calcd. for C₁₃H₁₈FNO (m.w. 223.29): C, 69.93%; H, 8.12%; N, 6.27%.
Found: C, 69.87%; H, 8.14%; N, 6.25%.

Example 19: (2S, 3S, 5R)-2-(3,4-difluorophenyl)-3,4,5-trimethylmorpholine hydrochloride.
m.p. 228-229°C. [α]_D²⁰ = + 35.9° (c = 0.691, 95% ethanol).

NMR-¹H: (DMSO-d₆) δ 1.08 (d, 3H, CH₃), 1.31 (d, 3H, CH₃), 2.81 (d, 3H, N-Me), 3.50 (broad m, 2H, CH), 3.80 (dd, 1H, CH₂, J = 10.64, 12.53), 4.02 (dd, 1H, CH₂, J = 3.55, 12.54), 4.65 (d, 1H, CH, J = 10.16), 7.23-7.58 (aromatic H's), 11.35 (broad, s, 1H, HCl).

Elemental Analysis: Calcd. for C₁₃H₁₈ClF₂NO (m.w. 277.44): C, 56.22%; H, 6.53%; N, 5.04%. Found: C, 56.22%; H, 6.57%; N, 4.98%.

Example 20: (2S, 3S, 5R)-2-(4-fluorophenyl)-3,4,5-trimethylmorpholine hydrochloride.
m.p. 193-194°C [α]_D^{20.5} = + 38.1° (c = 0.674, 95% ethanol).

NMR-¹H: (DMSO-d₆) δ 1.05 (d, 3H, CH₃), 1.31 (d, 3H, CH₃), 2.82 (d, 3H, N-Me), 3.49 (broad m, 2H, CH), 3.79 (dd, 1H, CH₂, J = 10.74, 12.65), 4.01 (dd, 1H, CH₂, J = 3.71, 12.70); 4.60 (d, 1H, CH, J = 9.96), 7.17-7.50 (aromatic H's), 11.21 (broad, s, 1H, HCl).

Elemental Analysis: Calcd. for C₁₃H₁₉ClFNO (m.w. 259.75): C, 60.11%; H, 7.37%; N, 5.39%. Found: C, 60.02%; H, 7.39%; N, 5.38%.

Example 21: (2R, 3R, 5S)-2-(3-fluorophenyl)-3,4,5-trimethylmorpholine hydrochloride.

m.p. 193-194°C $[\alpha]_D^{20} = -35.0^\circ$ (c = 0.696, 95% ethanol).

NMR-¹H: (DMSO-d₆) δ 1.07 (d, 3H, CH₃), 1.31 (d, 3H, CH₃), 2.82 (d, 3H, N-Me), 3.52 (broad m, 2H, CH), 3.80 (dd, 1H, CH₂, J = 10.94, 12.50), 4.02 (dd, 1H, CH₂, J = 3.60, 12.54); 4.62 (d, 1H, CH, J = 9.96), 7.17-7.51 (aromatic H's), 11.26 (broad, s, 1H, HCl).

Elemental Analysis: Calcd. for C₁₃H₁₉ClFNO (m.w. 259.75): C, 60.11%; H, 7.37%; N, 5.39%. Found: C, 60.22%; H, 7.39%; N, 5.41%.

Example 22: Antitetraabenazine Test:

Prevention of tetraabenazine-induced sedation was measured using a modification of the method of Vernier et al., First Hahnemann Symposium on Psychosomatic Medicine, ed. Nodim and Moyer, pub. Lea and Febiger, Philadelphia, 1962.

Mice, groups of 12 CD1 males each, were injected intraperitoneally (ip) with the hydrochloride salt of a compound of formula (I) in physiological saline solution or with physiological saline solution alone. Thirty minutes later each of the mice was injected (ip, 35 mg/kg) with a solution of tetraabenazine hydrochloride. Thirty minutes after the injection of tetraabenazine each mouse was examined for its level of exploratory behavior which was scored on a modification of the arbitrary scale defined by Vernier et. al. The result reported in Table I as the ED₅₀ value is the amount of the test compound required to reverse the tetraabenazine effects in 50 percent of the animals tested.

Table I
Antitetraabenazine Activity in the Mouse

Compound	ED ₅₀ (mg/kg i.p.)
Example 1 (HCl)	4
Example 2 (HCl)	8
Example 6 (HCl)	10
Example 7 (HCl)	4
Example 12 (HCl)	6
Example 13 (HCl)	4
Example 14 (HCl)	8
Example 16 (HCl)	8
Example 18	6

Example 23: Formulations

A. Tablet

<u>Ingredient</u>	<u>Amount per Tablet</u>
A compound of formula (I) (calculated as the base)	50 mg
Lactose	85 mg
Cornstarch	50 mg
Micronized Silica Gel	10 mg
Polyvinylpyrrolidone	5 mg

The lactose, cornstarch and compound of formula (I) are mixed together and granulated with a binder (polyvinylpyrrolidone in an alcoholic solution) to form granules. The

granules are passed through a 16-20 mesh screen, then air dried, lubricated with micronized silica gel and compressed into tablets. A film coat may then be applied if desired.

B. Capsule

<u>Ingredient</u>	<u>Amount per Capsule</u>
A compound of formula (I) (calculated as the base)	50 mg
Lactose	125 mg
Cornstarch	125 mg

The above ingredients are mixed and filled into a two piece hard gelatin capsule.

C. Parenteral Solution

A compound of formula (I) (as a pharmaceutically acceptable salt)	25 mg (calculated as the base)
Sterile Water for Injections, q.s. to	1.0 mL


A pharmaceutically acceptable salt of a compound of formula (I) is dissolved in sterile water under sterile conditions to make 1.0 mL. Such a solution may be packaged in a sealed sterile ampule to provide a unit dose or in a sterile vial for multiple doses. If the formulation is to be packed in a multi-dose container, the addition of a bacteriostat such as 0.2 to 0.5% w/v of phenol is desirable.

D. Suppository

The hydrochloride salt of a compound of formula (I) (50 mg, calculated as the base) is mixed with 250 mg of softened or melted cocoa butter, and a suppository is formed by chilling and shaping in a mold

CLAIMS

1. A compound of formula (I)




wherein

R and R¹ are each either hydrogen or fluorine and
 R² is hydrogen or methyl,
 and salts thereof.

2. A (+-)-(2R*,3R*,5S*) racemate according to claim 1, and salts thereof.
3. A (2S,3S,5R) compound according to claim 1, and salts thereof.
4. A (2R,3R,5S) compound according to claim 1, and salts thereof.
5. (+-)-(2R*,3R*,5S*)-2-(3-Fluorophenyl)-3,5-dimethylmorpholine and salts thereof.

6. (2S,3S,5R)-2-(3,4-Difluorophenyl)-3,5-dimethylmorpholine and salts thereof.
7. A salt of a compound according to any of claims 1 to 6.
8. A pharmaceutically acceptable salt of a compound according to any of claims 1 to 6.
9. The hydrochloride salt of a compound according to any of claims 1 to 6.
10. A compound according to any of claims 1 to 6, or a pharmaceutically acceptable salt thereof, for use in the medical treatment of a human being.
11. A compound according to any of claims 1 to 6, or a pharmaceutically acceptable salt thereof, for use in the treatment of a mental disorder in a human being.
12. A compound according to any of claims 1 to 6, or a pharmaceutically acceptable salt thereof, for use in the treatment of depression in a human being.
13. Use of a compound according to any of claims 1 to 6, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the medical treatment of a human being.

14. Use of a compound according to any of claims 1 to 6, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a mental disorder in a human being.
15. Use of a compound according to any of claims 1 to 6, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of depression in a human being.
16. A pharmaceutical formulation comprising a compound according to any of claims 1 to 6, or a pharmaceutically acceptable salt thereof, together with an acceptable carrier therefor.
17. A formulation according to claim 16 adapted for oral administration.
18. A formulation according to claim 17 in the form of a capsule or tablet.
19. A method for the preparation of a formulation according to any of claims 16 to 18 comprising admixture of the ingredients thereof.
20. A method for the preparation of a compound of formula (I)



or a salt thereof,


wherein

R and R¹ are each either hydrogen or fluorine and

R² is hydrogen or methyl,

said method comprising

a) cyclization of the corresponding compound (II)



wherein R, R¹ and R² are as defined in formula (I); or

b) when R^2 is methyl, methylation of the corresponding compound of formula (I) wherein R^2 is hydrogen; or

c) for the (2S,3S,5R) compounds and (2R,3R,5S) compounds, resolution of the corresponding (+-)-(2R*,3R*,5S*) racemate;

followed as appropriate by conversion of the product into the free base or a salt thereof.

21. A method according to claim 20 for the preparation of a (+-)-(2R*,3R*,5S*) racemate or a salt thereof.

22. A method according to claim 20 for the preparation of a (2S,3S,5R) compound or a salt thereof.

23. A method according to claim 20 for the preparation of a (2R,3R,5S) compound or a salt thereof.

24. A method according to claim 20a) for the preparation of (+-)-(2R*,3R*,5S*)-2-(3-fluorophenyl)-3,5-dimethylmorpholine, or a salt thereof, comprising cyclization of (1R*,2S*)-2-([(1RS)-2-hydroxy-1-methylethyl]amino)-1-(3-fluorophenyl)propanol.

25. A method according to claim 20a) for the preparation of (2S,3S,5R)-2-(3,4-difluorophenyl)-3,5-dimethylmorpholine, or a salt thereof, comprising cyclization of (1R,2S)-1-(3,4-difluorophenyl)-2-([(1R)-2-hydroxy-1-methylethyl]amino)propanol.

26. A method according to any of claims 20 to 25 wherein the product is isolated as a salt.
27. A method according to any of claims 20 to 25 wherein the product is isolated as a pharmaceutically acceptable salt.
28. A method according to any of claims 20 to 25 wherein the product is isolated as the hydrochloride salt.
29. A compound of formula (I) according to claim 20, or a salt thereof, when prepared by a method according to any of claims 20 to 28.
30. A method for the treatment of a mental disorder in a human being comprising the administration to the said human being of a therapeutic amount of a compound according to any of claims 1 to 6 or a pharmaceutically acceptable salt thereof.
31. A method for the treatment of depression in a human being comprising the administration to the said human being of an antidepressant amount of a compound according to any of claims 1 to 6 or a pharmaceutically acceptable salt thereof.
32. A method according to either of claims 30 and 31 wherein the said compound or salt is administered by the oral route.

33. A method according to any of claims 30 to 32 wherein the said compound or salt is administered together with an acceptable carrier therefor.
34. A method according to claim 33 wherein the said compound or salt is administered in the form of an orally ingestible capsule or tablet.
35. A compound according to any of claims 1 to 6 and salts thereof, substantially as herein described with particular reference to Examples 1 to 21.
36. A method substantially as herein described, with particular reference to Examples 1 to 21, for the preparation of a compound according to any of claims 1 to 6 and salts thereof.
37. A pharmaceutical formulation substantially as herein described with particular reference to Example 23.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 92/00733

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl.5 C 07 D 265/30 A 61 K 31/535		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl.5	C 07 D A 61 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	FR,A,2553411 (LABORATOIRE L. LAFON) 19 April 1985, see claims ---	1,13-20
A	GB,A, 851311 (J.R. GEIGY AG) 12 October 1960, see page 1, lines 33-45; claims ---	1,13-20
A	US,A,2997469 (W. HEEL et al.) 22 August 1961, see claims ---	1,20
A	GB,A,1336732 (ISTITUTO GENTILI SPA) 7 November 1973, see claims -----	1,13-20
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search 03-07-1992		Date of Mailing of this International Search Report 05.08.92
International Searching Authority EUROPEAN PATENT OFFICE		Signature of Authorized Officer J. Chouly

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

GB 9200733
SA 58666

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on 16/07/92
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR-A- 2553411	19-04-85	None	
GB-A- 851311		None	
US-A- 2997469		None	
GB-A- 1336732	07-11-73	None	

EPO FORM P0479

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82